But competition has intensified and the firm and the company is short on new product launches. Profits slide at India's Dr ReddyProfits at Indian drugmaker Dr Reddy's fell 93% as research costs rose and sales flagged. Sales were down more than 25% from the previous year to 1.4bn rupees in the face of strong competition both at home, and in the US and Europe. It also lost a key court case in March 2004, banning it from selling a version of Pfizer's popular hypertension drug Norvasc in the US. Dr Reddy's Indian competitors are gathering strength although they too face heavy competitive pressures.